First Republic Investment Management Inc. Grows Stake in Eli Lilly And Co (LLY)

First Republic Investment Management Inc. increased its position in shares of Eli Lilly And Co (NYSE:LLY) by 0.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 359,907 shares of the company’s stock after purchasing an additional 905 shares during the period. First Republic Investment Management Inc.’s holdings in Eli Lilly And Co were worth $38,621,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in LLY. Gyroscope Capital Management Group LLC boosted its stake in Eli Lilly And Co by 0.5% in the third quarter. Gyroscope Capital Management Group LLC now owns 89,849 shares of the company’s stock worth $10,334,000 after purchasing an additional 469 shares in the last quarter. Bbva Compass Bancshares Inc. boosted its stake in Eli Lilly And Co by 5.3% in the third quarter. Bbva Compass Bancshares Inc. now owns 9,349 shares of the company’s stock worth $1,003,000 after purchasing an additional 474 shares in the last quarter. Pinnacle Associates Ltd. boosted its stake in Eli Lilly And Co by 0.9% in the third quarter. Pinnacle Associates Ltd. now owns 54,057 shares of the company’s stock worth $5,801,000 after purchasing an additional 485 shares in the last quarter. Pure Financial Advisors Inc. boosted its stake in Eli Lilly And Co by 18.3% in the third quarter. Pure Financial Advisors Inc. now owns 3,166 shares of the company’s stock worth $340,000 after purchasing an additional 490 shares in the last quarter. Finally, Balasa Dinverno & Foltz LLC boosted its stake in Eli Lilly And Co by 15.9% in the third quarter. Balasa Dinverno & Foltz LLC now owns 3,629 shares of the company’s stock worth $389,000 after purchasing an additional 499 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

In other Eli Lilly And Co news, SVP Alfonso G. Zulueta sold 7,000 shares of the stock in a transaction dated Thursday, October 4th. The stock was sold at an average price of $114.64, for a total value of $802,480.00. Following the completion of the sale, the senior vice president now directly owns 45,224 shares in the company, valued at $5,184,479.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Alfonso G. Zulueta sold 6,000 shares of the stock in a transaction dated Tuesday, September 18th. The stock was sold at an average price of $106.31, for a total value of $637,860.00. Following the completion of the sale, the senior vice president now owns 55,224 shares of the company’s stock, valued at $5,870,863.44. The disclosure for this sale can be found here. Insiders sold 1,962,800 shares of company stock valued at $149,601,553 over the last 90 days. Corporate insiders own 0.11% of the company’s stock.

A number of research firms have commented on LLY. Zacks Investment Research raised Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $133.00 price objective on the stock in a research note on Wednesday. Citigroup lowered Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $113.00 price target on the stock. in a research note on Sunday, December 2nd. ValuEngine raised Eli Lilly And Co from a “hold” rating to a “buy” rating in a research note on Monday, November 12th. TheStreet raised Eli Lilly And Co from a “c+” rating to a “b+” rating in a research note on Tuesday, November 6th. Finally, Societe Generale set a $106.00 price target on Eli Lilly And Co and gave the company a “hold” rating in a research note on Wednesday, November 7th. Nine investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $111.53.

NYSE LLY opened at $115.84 on Friday. The stock has a market capitalization of $123.43 billion, a P/E ratio of 27.07, a P/E/G ratio of 1.82 and a beta of 0.31. The company has a quick ratio of 1.53, a current ratio of 1.91 and a debt-to-equity ratio of 0.83. Eli Lilly And Co has a 12 month low of $73.69 and a 12 month high of $119.84.

Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings data on Tuesday, November 6th. The company reported $1.39 EPS for the quarter, beating analysts’ consensus estimates of $1.35 by $0.04. The business had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $6.04 billion. Eli Lilly And Co had a return on equity of 42.84% and a net margin of 1.85%. The firm’s revenue was up 7.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.05 earnings per share. On average, equities research analysts predict that Eli Lilly And Co will post 5.58 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 10th. Shareholders of record on Thursday, November 15th will be issued a $0.5625 dividend. The ex-dividend date of this dividend is Wednesday, November 14th. This represents a $2.25 annualized dividend and a dividend yield of 1.94%. Eli Lilly And Co’s dividend payout ratio (DPR) is currently 52.57%.

ILLEGAL ACTIVITY NOTICE: “First Republic Investment Management Inc. Grows Stake in Eli Lilly And Co (LLY)” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/12/07/first-republic-investment-management-inc-grows-stake-in-eli-lilly-and-co-lly.html.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Further Reading: Are all No-Load Funds Equal?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply